adalimumab vs obefazimod
Same indication, different mechanisms: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Ulcerative Colitis
adalimumab: TNF-alpha · obefazimod: miR-124 · full Ulcerative Colitis pipeline
adalimumab · Humira
Marketed by AbbVie and partners
NCT00385736 · Phase 3 · completed
Design is strong (randomized, quadruple-blind, placebo-controlled, n=576, hard endoscopic/clinical Mayo remission endpoint), but the primary endpoint result was discordant across the two pre-specified dose-vs-placebo comparisons: one significant, one not. A well-designed trial with a mixed result is capped at moderate rather than strong.
Next expected readout: September 2027 · NCT06257875 (registry estimate)
Reported efficacy
Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8; Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 52: Proportion of Participants Who Achieved Clinical Remission Per Mayo Score at Week 8 (Week 8): Adalimumab 160/80/40 16.5% vs Placebo 9.3%; p=0.019 (Adalimumab 160/80/40 vs Placebo) (met)
Result source: NCT00408629
obefazimod
Developed by Abivax
NCT05507203 · Phase 3 · completed
The trial was randomized, blinded, and placebo-controlled with a hard clinical/endoscopic primary endpoint (clinical remission), and both the 25 mg and 50 mg doses produced significantly higher remission rates than placebo (23.8% and 21.7% vs 2.5%, both P<0.0001).
Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.
Next expected readout: March 2028 · NCT05177835 (registry estimate)
Reported efficacy
Rate of subjects in clinical remission at Week 44; Number and percentage of all treatment-emergent adverse events (TEAEs) (Week 44); Number and percentage of all serious adverse events (SAEs) (Week 44); Number and percentage of all causally related TEAEs/SAEs (Week 44): ABTECT maintenance, clinical remission at Week 44: placebo 10.4% (20), 25 mg 50.8% (98; placebo-adjusted +39.3%), 50 mg 51.3% (100; placebo-adjusted +40.3%), p<0.0001 (met)
Result source: NCT05535946
Results for Ulcerative Colitis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | adalimumab | obefazimod |
|---|---|---|
| Clinical remission (induction) | 10% vs 11.5%−1.5 vs placeboNCT008530996 other results
| 17.5% vs 12.5%+5 vs placeboNCT0376000310 other results
|
| Clinical remission (maintenance) | 20% vs 7.3%+12.7 vs placeboNCT0085309914 other results
| —Trial running · NCT05535946 |
| Clinical response (induction) | 50% vs 35.4%+14.6 vs placeboNCT008530994 other results
| 58.7% vs 34.4%+24.3 vs placeboNCT037600035 other results
|
| Endoscopic improvement (induction) | 44.4% vs 30.2%+14.2 vs placeboNCT008530992 other results
| —Trial running · NCT05535946 |
| Corticosteroid-free remission (maintenance) | 13.3% vs 5.7%+7.6 vs placeboNCT004086295 other results
| —Trial running · NCT05535946 |
Clinical remission (induction)
- adalimumab
- 10% vs 11.5%−1.5 vs placeboNCT00853099
6 other results
- 13.8% vs 11.5% NCT00853099
- 10% vs 9.2% NCT00385736
- 18.5% vs 9.2% NCT00385736
- 16.5% vs 9.3% NCT00408629
- 10% vs 11.5% NCT00853099
- 13.8% vs 11.5% NCT00853099
- obefazimod
- 17.5% vs 12.5%+5 vs placeboNCT03760003
10 other results
- 20% vs 13% NCT03760003
- 26.2% vs 12.5% NCT03760003
- 24.3% vs 13% NCT03760003
- 25% vs 12.5% NCT03760003
- 22.6% vs 13% NCT03760003
- 11.1% vs 35% NCT03093259
- 21.7% vs 2.5% NCT05507203
- 19.8% vs 6.3% NCT05507216
- 23.8% vs 2.5% NCT05507203
- 11.3% vs 6.3% NCT05507216
Clinical remission (maintenance)
- adalimumab
- 20% vs 7.3%+12.7 vs placeboNCT00853099
14 other results
- 26.4% vs 7.3% NCT00853099
- 17.3% vs 8.5% NCT00408629
- 29% vs 33.3% NCT02065557
- 45.2% vs 33.3% NCT02065557
- 27.3% vs 33.3% NCT02065557
- 42.9% vs 33.3% NCT02065557
- 20% vs 7.3% NCT00853099
- 17.8% vs 8.3% NCT00853099
- 26.4% vs 7.3% NCT00853099
- 17.2% vs 8.3% NCT00853099
- 42.9% vs 37.5% NCT02065557
- 45.5% vs 37.5% NCT02065557
- 42.9% vs 37.5% NCT02065557
- 44% vs 37.5% NCT02065557
- obefazimod
- —Trial running · NCT05535946
Clinical response (induction)
- adalimumab
- 50% vs 35.4%+14.6 vs placeboNCT00853099
4 other results
- 42.5% vs 35.4% NCT00853099
- 54.6% vs 44.6% NCT00385736
- 51.5% vs 44.6% NCT00385736
- 50.4% vs 34.6% NCT00408629
- obefazimod
- 58.7% vs 34.4%+24.3 vs placeboNCT03760003
5 other results
- 66.7% vs 43.5% NCT03760003
- 62.3% vs 34.4% NCT03760003
- 67.6% vs 43.5% NCT03760003
- 50% vs 34.4% NCT03760003
- 61.3% vs 43.5% NCT03760003
Endoscopic improvement (induction)
- adalimumab
- 44.4% vs 30.2%+14.2 vs placeboNCT00853099
2 other results
- 39.1% vs 30.2% NCT00853099
- 41.1% vs 31.7% NCT00408629
- obefazimod
- —Trial running · NCT05535946
Corticosteroid-free remission (maintenance)
- adalimumab
- 13.3% vs 5.7%+7.6 vs placeboNCT00408629
5 other results
- 13.3% vs 5.7% NCT00408629
- 30.8% vs 40% NCT02065557
- 31.3% vs 40% NCT02065557
- 26.7% vs 40% NCT02065557
- 35.3% vs 40% NCT02065557
- obefazimod
- —Trial running · NCT05535946
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
7 other shared endpoints and safety
Coverage. adalimumab: 11 of 11 rows · obefazimod: 11 of 11 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | adalimumab Rows use multiple source trials | obefazimod Rows use multiple source trials |
|---|---|---|
| Clinical Remission responder rate · % of participants No placebo or comparator arm | 61.2% (n=585) @ 48wk40 mg EOW/EWa,b,c NCT00573794 · Phase 3 · monotherapy | 54.8% (n=217) @ 48wk*50mga,b,c NCT04023396 · Phase 2 · registry result, not featured evidence · converted to % from 119 Participants as posted |
| Endoscopic Improvement event count · % of participants Induction | 46.9% (n=130) vs 41.5% (n=130) placebo @ 8wk160/80/40d,a,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose37.7% (n=130) vs 41.5% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 39.6% (n=53) vs 13.6% (n=59) placebo @ 8wk*50 mgd,a,b,c NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 21 Participants as posted show 2 more doses34.5% (n=58) vs 13.6% (n=59) placebo @ 8wk*25 mg NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted 44.4% (n=54) vs 13.6% (n=59) placebo @ 8wk*100 mg NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted |
| Partial Mayo absolute change · score No placebo or comparator arm | -2 score @ 388wk40 mg EOW/EWa,b,c,e NCT00573794 · Phase 3 · monotherapy | -2.2 scorea,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence |
| Rectal Bleeding Subscore 0 1 event count · % of participants Induction | 77.7% (n=130) vs 66.2% (n=130) placebo @ 8wk160/80/40d,a,b,c NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 1 more dose70% (n=130) vs 66.2% (n=130) placebo @ 8wk80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 72.1% (n=61) vs 51.6% (n=64) placebo @ 8wk*50 mgd,a,b,c NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 44 Participants as posted show 2 more doses76.7% (n=60) vs 51.6% (n=64) placebo @ 8wk*25 mg NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 46 Participants as posted 76.2% (n=63) vs 51.6% (n=64) placebo @ 8wk*100 mg NCT03760003 · Phase 2 · registry result, not featured evidence · converted to % from 48 Participants as posted |
| SF-36 MCS absolute change · score No placebo or comparator arm | -7.3 score @ 388wk40 mg EOW/EWa,b,c,e NCT00573794 · Phase 3 · monotherapy | 6.38 scorea,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence |
| SF-36 PCS absolute change · score No placebo or comparator arm | 8.4 score @ 388wk40 mg EOW/EWa,b,c,e NCT00573794 · Phase 3 · monotherapy | 4.82 scorea,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence |
| Total Mayo absolute change · score No placebo or comparator arm | -2 score @ 388wk40 mg EOW/EWa,b,c,e NCT00573794 · Phase 3 · monotherapy | -3 scorea,b,c,e NCT03368118 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 6.9%160/80/40f NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results9.2%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 37.6%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 52.5% NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 10.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 56.4%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 34.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 33.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 23.8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 24.4%50mgg NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results50% NCT03368118 · Phase 2 · registry result, not featured evidence 15.9%50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence 7.9%25 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25mg NCT03760003 · Phase 2 · registry result, not featured evidence 15.6%100 mg NCT03760003 · Phase 2 · registry result, not featured evidence —100mg NCT03760003 · Phase 2 · registry result, not featured evidence —ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence 8.7%ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 3.1%160/80/40f NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results4.6%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5%160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 —Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 — NCT02632175 · Phase 3 · monotherapy —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 —standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.3%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.4%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 —Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 13.8%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 14.3%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 10.3%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 5.6% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 7.4%50mgg NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results— NCT03368118 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25mg NCT03760003 · Phase 2 · registry result, not featured evidence —100 mg NCT03760003 · Phase 2 · registry result, not featured evidence —100mg NCT03760003 · Phase 2 · registry result, not featured evidence —ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence 4.3%ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4%160/80/40f NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 18 more results3.8%80/40 NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 —160/80/40 NCT00408629 · Phase 3 · Ulcerative Colitis · phase 3 12.1%Adalimumab Group - Double-Blind Pe NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 27.1% NCT02632175 · Phase 3 · monotherapy 7.8%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 5.6%open-label high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.6%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 13.9%high dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 15.2%standard dose NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 3.8%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 5%Induction (Main Study + Japan Sub- NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.6%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 12.8%Maintenance (Main Study + Japan Su NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 9.9%Maintenance (Main Study): TDM Regi NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 26.7%40 mg EOW/EW NCT00573794 · Phase 3 · monotherapy 11.1%160 mg/80 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 16.1%80 mg/40 mg NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 14.5% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 8.3%50mgg NCT04023396 · Phase 2 · registry result, not featured evidence show 9 more results13.6% NCT03368118 · Phase 2 · registry result, not featured evidence —50 mg NCT03760003 · Phase 2 · registry result, not featured evidence 6.3%50 mg NCT03760003 · Phase 2 · registry result, not featured evidence —25 mg NCT03760003 · Phase 2 · registry result, not featured evidence 1.6%25mg NCT03760003 · Phase 2 · registry result, not featured evidence —100 mg NCT03760003 · Phase 2 · registry result, not featured evidence 6.3%100mg NCT03760003 · Phase 2 · registry result, not featured evidence 0%ABX464 NCT03093259 · Phase 2 · registry result, not featured evidence —ABX464 Treatment Arm NCT03093259 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 160/80/40f colitis ulcerative 4% (placebo 3.6%) fatigue 4% (placebo 2.2%) headache 3.1% (placebo 7.2%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 show 17 more results80/40 headache 6.9% (placebo 7.2%) colitis ulcerative 5.4% (placebo 3.6%) nasopharyngitis 4.6% (placebo 1.8%) NCT00385736 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 nasopharyngitis 17.5% (placebo 10.4%) colitis ulcerative 16.3% (placebo 22.3%) headache 8.6% (placebo 14.2%) NCT00408629 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 33.9% upper respiratory tract infection 27.1% nasopharyngitis 22% NCT02632175 · Phase 3 · monotherapy high dose headache 9.8% (placebo 16.7%) anaemia 5.9% (placebo 8.3%) nausea 5.9% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 open-label high dose headache 22.2% (placebo 16.7%) abdominal pain 11.1% (placebo 8.3%) oropharyngeal pain 11.1% (placebo 0%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 12.5% (placebo 16.7%) colitis ulcerative 6.3% (placebo 16.7%) nasopharyngitis 6.3% (placebo 8.3%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 high dose colitis ulcerative 11.1% (placebo 16.7%) nasopharyngitis 11.1% (placebo 8.3%) upper respiratory tract infection 11.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 standard dose headache 18.2% (placebo 16.7%) c-reactive protein increased 9.1% (placebo 0%) colitis ulcerative 9.1% (placebo 16.7%) NCT02065557 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 8.4% nasopharyngitis 5.1% arthralgia 3.1% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 headache 6.1% colitis ulcerative 5.3% nasopharyngitis 4.2% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 13.4% nasopharyngitis 13.1% arthralgia 6.6% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 17.4% nasopharyngitis 13.6% arthralgia 6.7% NCT02065622 · Phase 3 · combination · Ulcerative Colitis · phase 3 colitis ulcerative 15.2% nasopharyngitis 7.3% upper respiratory tract infection 6% NCT02065622 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 40 mg EOW/EW colitis ulcerative 30.4% viral upper respiratory tract infection 19.4% arthralgia 10.5% NCT00573794 · Phase 3 · monotherapy 160 mg/80 mg nasopharyngitis 33.3% (placebo 21.9%) iron deficiency anaemia 8.9% (placebo 7.3%) headache 7.8% (placebo 6.3%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 80 mg/40 mg nasopharyngitis 21.8% (placebo 21.9%) injection site reaction 8% (placebo 2.1%) dental caries 6.9% (placebo 5.2%) NCT00853099 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 colitis ulcerative 13.2% headache 13% nasopharyngitis 8% NCT01550965 · Phase 3 · monotherapy · Ulcerative Colitis · phase 3 | 50mgg covid-19 14.3% headache 11.5% colitis ulcerative 7.8% NCT04023396 · Phase 2 · registry result, not featured evidence show 5 more resultscolitis ulcerative 31.8% abdominal pain 22.7% nasopharyngitis 22.7% NCT03368118 · Phase 2 · registry result, not featured evidence 50 mg headache 30.2% (placebo 7.8%) nausea 6.3% (placebo 6.3%) abdominal pain upper 4.8% (placebo 0%) NCT03760003 · Phase 2 · registry result, not featured evidence 25mg headache 21% (placebo 7.8%) nausea 8.1% (placebo 6.3%) abdominal pain upper 4.8% (placebo 0%) NCT03760003 · Phase 2 · registry result, not featured evidence 100mg headache 42.2% (placebo 7.8%) nausea 14.1% (placebo 6.3%) arthralgia 7.8% (placebo 4.7%) NCT03760003 · Phase 2 · registry result, not featured evidence abdominal pain 17.4% (placebo 11.1%) headache 17.4% (placebo 0%) abdominal pain upper 13% (placebo 0%) NCT03093259 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for 2 of these studies.
- gPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
adalimumab
show 1 more result
show 1 more result
show 4 more results
show 14 more results
show 8 more results
show 2 more results
show 8 more results
show 5 more results
+ 42 further endpoints in the CSV export.
obefazimod
show 2 more results
show 2 more results
show 2 more results
+ 59 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: adalimumab's landscape · obefazimod's landscape